The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review
- Author(s)
- Lai-Kwon, J; Cohen, JE; Lisy, K; Rutherford, C; Girgis, A; Basch, E; Jefford, M;
- Journal Title
- JCO Clinical Cancer Informatics
- Publication Type
- Review
- Abstract
- PURPOSE: Increasing use of immune checkpoint inhibitors (ICIs) in routine cancer care will increase the incidence of immune-related adverse events (irAEs). Systems are needed to support remote monitoring for irAEs. Electronic patient-reported outcome (ePRO) symptom monitoring systems can help monitor and manage symptoms and side effects. We assessed the content and features of ePRO symptom monitoring systems for irAEs, and their feasibility, acceptability, and impact on patient outcomes and health care utilization. METHODS: A systematic literature search was conducted in May 2022 on MEDLINE, Embase, PsycINFO, and Cochrane Central Register of Controlled Trials. Quantitative and qualitative data relevant to the review questions were extracted and synthesized in tables. RESULTS: Seven papers describing five ePRO systems were included. All systems collected PROs between clinic visits. Two of five used validated symptom questionnaires, 3/5 provided prompts to complete questionnaires, 4/5 provided reminders to self-report, and 3/5 provided clinician alerts for severe/worsening side effects. Four of five provided coverage of >/=26/30 irAEs in the ASCO irAE guideline. Feasibility and acceptability were demonstrated with consent rates of 54%-100%, 17%-27% of questionnaires generating alerts, and adherence rates of 74%-75%. One paper showed a reduction in grade 3-4 irAEs, treatment discontinuation, clinic visit duration, and emergency department presentations, while another showed no difference in these outcomes or the rate of steroid use. CONCLUSION: There is preliminary evidence of the feasibility and acceptability of ePRO symptom monitoring for irAEs. However, further studies are needed to confirm the impact on ICI-specific outcomes, such as the frequency of grade 3-4 irAEs and duration of immunosuppression. Suggestions for the content and features of future ePRO systems for irAEs are provided.
- Publisher
- American Society of Clinical Oncology
- Keywords
- Humans; Feasibility Studies; *Immune Checkpoint Inhibitors; *Ambulatory Care; Patient Reported Outcome Measures; Electronics
- Department(s)
- Medical Oncology; Health Services Research; Australian Cancer Survivorship Centre
- PubMed ID
- 37220322
- Publisher's Version
- https://doi.org/10.1200/CCI.22.00185
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-08-16 07:49:59
Last Modified: 2023-08-16 07:51:43